ReShape Lifesciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ReShape Lifesciences, Inc.
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
- Implantable Devices
- Rehabilitation Equipment and Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Disease Management
- Other Names / Subsidiaries
- BarioSurg Inc.
- EnteroMedics, Inc.
- Onciomed Inc.
- ReShape Medical
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.